SUPPLEMENT

Q2 2022 — Non-GAAP reconciliations

Q2 2022PDF · 22 pages366 KB
DANAHER CORPORATION
RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES AND SUPPLEMENTAL
INFORMATION
THREE AND SIX-MONTH PERIODS ENDED JULY 1, 2022 AND JULY 2, 2021

-- 1 of 22 --

TABLE OF CONTENTS
Page
1 Core Sales Growth by Segment and Base Business Core Sales Growth
2 Forecasted Core Sales Growth and Base Business Core Sales Growth
3 Segment Sales, Operating Profit and Adjusted Operating Profit
4 Adjusted EBITDA and Adjusted EBITDA Margin
8 Other Non-GAAP Adjusted P&L Measures
13 Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
15 Year-Over-Year Core Operating Margin Changes from Continuing Operations
16 Free Cash Flow from Continuing Operations and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations
Conversion Ratio
17 Statement Regarding Non-GAAP Measures
19 Supplemental Information
FORWARD-LOOKING STATEMENTS DISCLOSURE
Statements in this document that are not strictly historical, including any statements regarding events or developments that we believe or anticipate will or may occur in the future are "forward-looking" statements
within the meaning of the federal securities laws. There are a number of important factors that could cause actual results, developments and business decisions to differ materially from those suggested or indicated
by such forward-looking statements and you should not place undue reliance on any such forward-looking statements. These factors include, among other things, the highly uncertain and unpredictable severity,
magnitude and duration of the COVID-19 pandemic (and the related governmental, business and community responses thereto) on our business, results of operations and financial condition, the impact of our debt
obligations on our operations and liquidity, deterioration of or instability in the economy, the markets we serve and the financial markets (including as a result of the COVID-19 pandemic), uncertainties relating to
U.S. laws or policies, including potential changes in U.S. trade policies and tariffs and the reaction of other countries thereto, contractions or growth rates and cyclicality of markets we serve, competition, our
ability to develop and successfully market new products and technologies and expand into new markets, the potential for improper conduct by our employees, agents or business partners, our compliance with
applicable laws and regulations (including rules relating to off-label marketing and other regulations relating to medical devices and the health care industry), the results of our clinical trials and perceptions thereof,
our ability to effectively address cost reductions and other changes in the health care industry, our ability to successfully identify and consummate appropriate acquisitions and strategic investments and successfully
complete divestitures and other dispositions, our ability to integrate the businesses we acquire and achieve the anticipated growth, synergies and other benefits of such acquisitions, contingent liabilities and other
risks relating to acquisitions, investments, strategic relationships and divestitures (including tax-related and other contingent liabilities relating to past and future IPOs, split-offs or spin-offs), security breaches or
other disruptions of our information technology systems or violations of data privacy laws, the impact of our restructuring activities on our ability to grow, risks relating to potential impairment of goodwill and
other intangible assets, currency exchange rates, tax audits and changes in our tax rate and income tax liabilities, changes in tax laws applicable to multinational companies, litigation and other contingent liabilities
including intellectual property and environmental, health and safety matters, the rights of the United States government to use, disclose and license certain intellectual property we license if we fail to
commercialize it, risks relating to product, service or software defects, product liability and recalls, risks relating to product manufacturing, our relationships with and the performance of our channel partners,
uncertainties relating to collaboration arrangements with third-parties, commodity costs and surcharges, our ability to adjust purchases and manufacturing capacity to reflect market conditions, reliance on sole
sources of supply, the impact of deregulation on demand for our products and services, the impact of climate change, or legal or regulatory measures to address climate change, labor matters and our ability to
recruit, retain and motivate talented employees, international economic, political, legal, compliance, social and business factors (including the impact of the military conflict between Russia and Ukraine and the
impact of the United Kingdom's separation from the European Union), disruptions relating to man-made and natural disasters (including pandemics such as COVID-19) and pension plan costs. Additional
information regarding the factors that may cause actual results to differ materially from these forward-looking statements is available in our SEC filings, including our 2021 Annual Report on Form 10-K and
Quarterly Report on Form 10-Q for the second quarter of 2022. These forward-looking statements speak only as of the date of this document (July 20, 2022) and except to the extent required by applicable law, the
Company does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events and developments or otherwise.

-- 2 of 22 --

% Change Three-Month Period Ended July 1, 2022 vs. Comparable 2021 Period
Segments
Total Company Life Sciences Diagnostics Environmental &
Applied Solutions
Total sales growth (GAAP) 7.5 % 6.0 % 9.5 % 6.5 %
Impact of:
Acquisitions/divestitures (2.5) % (4.0) % (1.0) % — %
Currency exchange rates 4.5 % 5.0 % 4.0 % 3.5 %
Core sales growth (non-GAAP) 9.5 % 7.0 % 12.5 % 10.0 %
Impact of COVID-19 related testing (1.5) %
Base business core sales growth (non-GAAP) 8.0 %
% Change Six-Month Period Ended July 1, 2022 vs. Comparable 2021 Period
Segments
Total Company Life Sciences Diagnostics Environmental &
Applied Solutions
Total sales growth (GAAP) 9.5 % 8.0 % 15.5 % 4.5 %
Impact of:
Acquisitions/divestitures (2.5) % (4.0) % (1.0) % 1.0 %
Currency exchange rates 3.5 % 3.0 % 3.0 % 3.0 %
Core sales growth (non-GAAP) 10.5 % 7.0 % 17.5 % 8.5 %
Impact of COVID-19 related testing (2.5) %
Base business core sales growth (non-GAAP) 8.0 %
Note: While we expect overall demand for the Company’s COVID-19 related products to moderate as and to the extent the pandemic subsides, as the pandemic evolves toward endemic
status we believe a level of demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to prevent or mitigate similar, future
pandemics) and COVID-19 testing will continue. However, on a relative basis, we expect the level of ongoing demand for products supporting COVID-19 testing will be subject to more
fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and therapeutics. Therefore, beginning with the first quarter of 2022, in addition to
disclosing core revenue growth, we disclose “base business core sales growth” on a basis that excludes revenues related to COVID-19 testing and includes revenues from products that
support COVID-19 related vaccines and therapeutics. We believe this additional measure provides useful information to investors by facilitating period-to-period comparisons of our
financial performance and identifying underlying growth trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 testing as a result of the
pandemic.
DANAHER CORPORATION
Core Sales Growth by Segment and Base Business Core Sales Growth
1

-- 3 of 22 --

% Change Three-Month
Period Ending September
30, 2022 vs. Comparable
2021 Period
% Change Year Ending
December 31, 2022 vs.
Comparable 2021
Period
Core sales growth (non-GAAP) +Low-single digit +Mid-single digit
Impact of COVID-19 related testing +Mid-single digit +Low-single digit
Base business core sales growth (non-GAAP) +High-single digit +High-single digit
1 We do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in predicting and estimating the future impact and timing of currency translation,
acquisitions and divested product lines, which would be reflected in any forecasted GAAP revenue.
DANAHER CORPORATION
Forecasted Core Sales Growth and Base Business Core Sales Growth 1
2

-- 4 of 22 --

Sales (GAAP)
Life Sciences $ 3,967 $ 3,734 $ 7,849 $ 7,280
Diagnostics 2,561 2,336 5,205 4,514
Environmental & Applied Solutions 1,223 1,148 2,385 2,282
Total Company $ 7,751 $ 7,218 $ 15,439 $ 14,076
Operating Profit (GAAP)
Life Sciences $ 1,174 $ 1,144 $ 2,292 $ 2,295
Diagnostics 800 649 1,686 1,275
Environmental & Applied Solutions 307 280 543 565
Other (76) (68) (144) (133)
Total Company $ 2,205 $ 2,005 $ 4,377 $ 4,002
Amortization of Intangible Assets (GAAP)
Life Sciences $ 310 $ 280 $ 631 $ 557
Diagnostics 50 51 101 102
Environmental & Applied Solutions 13 16 27 32
Total Company $ 373 $ 347 $ 759 $ 691
Other Operating Profit Adjustments 2
Life Sciences $ — $ — $ 38 $ 46
Diagnostics — — 3 10
Environmental & Applied Solutions 9 — 10 —
Other — — 1 —
Total Company $ 9 $ — $ 52 $ 56
Adjusted Operating Profit (non-GAAP) 3
Life Sciences $ 1,484 $ 1,424 $ 2,961 $ 2,898
Diagnostics 850 700 1,790 1,387
Environmental & Applied Solutions 329 296 580 597
Other (76) (68) (143) (133)
Total Company $ 2,587 $ 2,352 $ 5,188 $ 4,749
Three-Month Period Ended Six-Month Period Ended
July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
3 Adjusted Operating Profit (non-GAAP) is defined as operating profit (GAAP) plus amortization of intangible assets (GAAP) plus (minus) Other Operating Profit Adjustments (as defined).
DANAHER CORPORATION
Segment Sales, Operating Profit and Adjusted Operating Profit
($ in millions)
3

-- 5 of 22 --

Three-Month Period Ended July 1, 2022
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 1,680
Interest, Net 49
Other Nonoperating (Income) Expense 87
Income Taxes 389
Operating Profit (GAAP) $ 1,174 $ 800 $ 307 $ (76) $ 2,205
Other Operating Profit Adjustments 2 — — 9 — 9
Depreciation 70 98 10 1 179
Amortization of Intangible Assets 310 50 13 — 373
Adjusted EBITDA (Non-GAAP) $ 1,554 $ 948 $ 339 $ (75) $ 2,766
Interest, Net (49)
Other Nonoperating Income (Expense) (87)
Income Taxes (389)
Other Operating Profit Adjustments 2 (9)
Depreciation (179)
Amortization of Intangible Assets (373)
Net Earnings from Continuing Operations (GAAP) $ 1,680
Sales (GAAP) $ 3,967 $ 2,561 $ 1,223 $ 7,751
Net Earnings from Continuing Operations Margin (GAAP) 21.7 %
Adjusted EBITDA Margin (Non-GAAP) 4 39.2 % 37.0 % 27.7 % 35.7 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
4

-- 6 of 22 --

Three-Month Period Ended July 2, 2021
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 1,699
Interest, Net 59
Other Nonoperating (Income) Expense (97)
Income Taxes 344
Operating Profit (GAAP) $ 1,144 $ 649 $ 280 $ (68) $ 2,005
Other Operating Profit Adjustments 2 — — — — —
Depreciation 64 102 11 1 178
Amortization of Intangible Assets 280 51 16 — 347
Adjusted EBITDA (Non-GAAP) $ 1,488 $ 802 $ 307 $ (67) $ 2,530
Interest, Net (59)
Other Nonoperating Income (Expense) 97
Income Taxes (344)
Other Operating Profit Adjustments 2 —
Depreciation (178)
Amortization of Intangible Assets (347)
Net Earnings from Continuing Operations (GAAP) $ 1,699
Sales (GAAP) $ 3,734 $ 2,336 $ 1,148 $ 7,218
Net Earnings from Continuing Operations Margin (GAAP) 23.5 %
Adjusted EBITDA Margin (Non-GAAP) 4 39.9 % 34.3 % 26.7 % 35.1 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
5

-- 7 of 22 --

Six-Month Period Ended July 1, 2022
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 3,405
Interest, Net 102
Other Nonoperating (Income) Expense 107
Income Taxes 763
Operating Profit (GAAP) $ 2,292 $ 1,686 $ 543 $ (144) $ 4,377
Other Operating Profit Adjustments 2 38 3 10 1 52
Depreciation 142 192 21 3 358
Amortization of Intangible Assets 631 101 27 — 759
Adjusted EBITDA (Non-GAAP) $ 3,103 $ 1,982 $ 601 $ (140) $ 5,546
Interest, Net (102)
Other Nonoperating Income (Expense) (107)
Income Taxes (763)
Other Operating Profit Adjustments 2 (52)
Depreciation (358)
Amortization of Intangible Assets (759)
Net Earnings from Continuing Operations (GAAP) $ 3,405
Sales (GAAP) $ 7,849 $ 5,205 $ 2,385 $ 15,439
Net Earnings from Continuing Operations Margin (GAAP) 22.1 %
Adjusted EBITDA Margin (Non-GAAP) 4 39.5 % 38.1 % 25.2 % 35.9 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
6

-- 8 of 22 --

Six-Month Period Ended July 2, 2021
Life Sciences Diagnostics
Environmental
& Applied
Solutions Other Total Company
Net Earnings from Continuing Operations (GAAP) $ 3,401
Interest, Net 113
Other Nonoperating (Income) Expense (237)
Income Taxes 725
Operating Profit (GAAP) $ 2,295 $ 1,275 $ 565 $ (133) $ 4,002
Other Operating Profit Adjustments 2 46 10 — — 56
Depreciation 116 195 22 3 336
Amortization of Intangible Assets 557 102 32 — 691
Adjusted EBITDA (Non-GAAP) $ 3,014 $ 1,582 $ 619 $ (130) $ 5,085
Interest, Net (113)
Other Nonoperating Income (Expense) 237
Income Taxes (725)
Other Operating Profit Adjustments 2 (56)
Depreciation (336)
Amortization of Intangible Assets (691)
Net Earnings from Continuing Operations (GAAP) $ 3,401
Sales (GAAP) $ 7,280 $ 4,514 $ 2,282 $ 14,076
Net Earnings from Continuing Operations Margin (GAAP) 24.2 %
Adjusted EBITDA Margin (Non-GAAP) 4 41.4 % 35.0 % 27.1 % 36.1 %
2 Refer to the Reconciliation of GAAP to Adjusted P&L Measures for a description of the components of Other Operating Profit Adjustments.
4 Adjusted EBITDA Margin (Non-GAAP) is defined as Adjusted EBITDA (Non-GAAP) divided by sales.
DANAHER CORPORATION
Adjusted EBITDA and Adjusted EBITDA Margin
($ in millions)
7

-- 9 of 22 --

Three-Month Period Ended July 1, 2022
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before income
taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common
share from
continuing
operations 5
Reported (GAAP) $ 7,751 $ (3,030) 60.9 % $ 2,205 28.4 % $ 2,069 $ (389) $ 1,658 J $ 2.25
Amortization of acquisition-related
intangible assets A — — — 373 4.8 373 373 0.50
Fair value net (gains) losses on
investments B — — — — — 98 98 0.13
Impairments and other charges C — — — 9 0.1 9 9 0.01
Tax effect of the above adjustments G (98) (98) (0.13)
Discrete tax adjustments H (8) (8) (0.01)
MCPS "as if converted" I — — — — — — — 22 —
Rounding — — — — 0.1 — — — 0.01
Adjusted (Non-GAAP) $ 7,751 $ (3,030) 60.9 % $ 2,587 33.4 % $ 2,549 $ (495) $ 2,054 $ 2.76
Three-Month Period Ended July 1, 2022
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 7,751 $ (2,085) (26.9) % $ (431) (5.6) % $ (87) $ (49)
Amortization of acquisition-related
intangible assets A — 373 4.8 — — — —
Fair value net (gains) losses on
investments B — — — — — 98 —
Impairments and other charges C — 9 0.1 — — — —
Rounding — — — — — — —
Adjusted (Non-GAAP) $ 7,751 $ (1,703) (22.0) % $ (431) (5.6) % $ 11 $ (49)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
8

-- 10 of 22 --

Three-Month Period Ended July 2, 2021
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before income
taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common
share from
continuing
operations 5
Reported (GAAP) $ 7,218 $ (2,821) 60.9 % $ 2,005 27.8 % $ 2,043 $ (344) $ 1,678 J $ 2.28
Amortization of acquisition-related
intangible assets A — — — 347 4.8 347 347 0.47
Fair value net (gains) losses on
investments B — — — — — (86) (86) (0.12)
Tax effect of the above adjustments G (53) (53) (0.07)
Discrete tax adjustments H (76) (76) (0.10)
MCPS "as if converted" I — — — — — — — 21 —
Adjusted (Non-GAAP) $ 7,218 $ (2,821) 60.9 % $ 2,352 32.6 % $ 2,304 $ (473) $ 1,831 $ 2.46
Three-Month Period Ended July 2, 2021
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 7,218 $ (1,966) (27.2) % $ (426) (5.9) % $ 97 $ (59)
Amortization of acquisition-related
intangible assets A — 347 4.8 — — — —
Fair value net (gains) losses on
investments B — — — — — (86) —
Adjusted (Non-GAAP) $ 7,218 $ (1,619) (22.4) % $ (426) (5.9) % $ 11 $ (59)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
9

-- 11 of 22 --

Six-Month Period Ended July 1, 2022
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before income
taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common share
from
continuing
operations 5
Reported (GAAP) $ 15,439 $ (6,013) 61.1 % $ 4,377 28.4 % $ 4,168 $ (763) $ 3,362 J $ 4.56
Amortization of acquisition-related
intangible assets A — — — 759 4.9 759 759 1.02
Fair value net (gains) losses on
investments B — — — — — 122 122 0.16
Impairments and other charges C — 18 0.1 52 0.3 52 52 0.07
Loss on partial settlement of a defined
benefit plan D — — — — — 10 10 0.01
Tax effect of the above adjustments G (183) (183) (0.24)
Discrete tax adjustments H (49) (49) (0.07)
MCPS "as if converted" I — — — — — — — 43 —
Rounding — — — — — — — — 0.01
Adjusted (Non-GAAP) $ 15,439 $ (5,995) 61.2 % $ 5,188 33.6 % $ 5,111 $ (995) $ 4,116 $ 5.52
Six-Month Period Ended July 1, 2022
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 15,439 $ (4,177) (27.1) % $ (872) (5.6) % $ (107) $ (102)
Amortization of acquisition-related
intangible assets A — 759 4.9 — — — —
Fair value net (gains) losses on
investments B — — — — — 122 —
Impairments and other charges C — 34 0.2 — — — —
Loss on partial settlement of a defined
benefit plan D — — — — — 10 —
Rounding — — 0.1 — — — —
Adjusted (Non-GAAP) $ 15,439 $ (3,384) (21.9) % $ (872) (5.6) % $ 25 $ (102)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
10

-- 12 of 22 --

Six-Month Period Ended July 2, 2021
Sales Cost of sales Gross profit
margin Operating
profit Operating
profit margin
Earnings
from
continuing
operations
before income
taxes Income taxes
Net earnings from
continuing
operations for
calculation of
diluted earnings
per common share
Diluted net
earnings per
common share
from
continuing
operations 5
Reported (GAAP) $ 14,076 $ (5,426) 61.5 % $ 4,002 28.4 % $ 4,126 $ (725) $ 3,359 J $ 4.57
Amortization of acquisition-related
intangible assets A — — — 691 4.9 691 691 0.93
Fair value net (gains) losses on
investments B — — — — — (202) (202) (0.27)
Impairments and other charges C — — — 10 0.1 10 10 0.01
Acquisition-related items E 17 29 0.3 46 0.3 46 46 0.06
Gain on disposition of certain product
lines F — — — — — (13) (13) (0.02)
Tax effect of the above adjustments G (110) (110) (0.15)
Discrete tax adjustments H (120) (120) (0.16)
MCPS "as if converted" I — — — — — — — 42 —
Rounding — — (0.1) — — — — — 0.01
Adjusted (Non-GAAP) $ 14,093 $ (5,397) 61.7 % $ 4,749 33.7 % $ 4,658 $ (955) $ 3,703 $ 4.98
Six-Month Period Ended July 2, 2021
Sales
Selling,
general and
administrative
expenses
Selling,
general and
administrative
expenses as a
% of sales
Research and
development
expenses
Research and
development
expenses as a
% of sales
Nonoperating
income
(expense), net
(excluding
interest)
Interest
income
(expense), net
Reported (GAAP) $ 14,076 $ (3,842) (27.3) % $ (806) (5.7) % $ 237 $ (113)
Amortization of acquisition-related
intangible assets A — 691 4.9 — — — —
Fair value net (gains) losses on
investments B — — — — — (202) —
Impairments and other charges C — 10 0.1 — — — —
Acquisition-related items E 17 — — — — — —
Gain on disposition of certain product
lines F — — — — — (13) —
Adjusted (Non-GAAP) $ 14,093 $ (3,141) (22.3) % $ (806) (5.7) % $ 22 $ (113)
5 Each of the per share amounts above have been calculated assuming the Mandatory Convertible Preferred Stock (“MCPS”) had been converted into shares of common stock. Net earnings per
diluted common share amounts for the relevant three-month periods may not add to the year-to-date amounts due to rounding.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
11

-- 13 of 22 --

A Amortization of acquisition-related intangible assets in the following historical periods ($ in millions) (only the pretax amounts set forth below are reflected in
the amortization line item above):
Three-Month Period Ended Six-Month Period Ended
July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021
Pretax $ 373 $ 347 $ 759 $ 691
After-tax 300 275 611 549
B Net (gains) losses on the Company's equity and limited partnership investments recorded in the following historical periods ($ in millions) (only the pretax
amounts set forth below are reflected in the fair value net (gains) losses on investments line above):
Three-Month Period Ended Six-Month Period Ended
July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021
Pretax (gain) loss $ 98 $ (86) $ 122 $ (202)
After-tax (gain) loss 75 (67) 93 (161)
C Impairment charges related to technology and customer relationships in the Environmental & Applied Solutions segment recorded in the three and six-month
periods ended July 1, 2022 ($9 million pretax as reported in this line item, $7 million after-tax). In the six-month period ended July 1, 2022, additional charges
incurred primarily related to impairments of accounts receivable and inventory as well as accruals for contractual obligations in Russia ($43 million pretax as
reported in this line item, $40 million after-tax, respectively). Impairment charges related to a trade name in the Diagnostics segment recorded in the six-month
period ended July 2, 2021 ($10 million pretax as reported in this line item, $8 million after-tax).
D Loss on a partial settlement of a defined benefit plan as a result of the transfer of a portion of the Company’s non-U.S. pension liabilities related to one defined
benefit plan to a third party in the six-month period ended July 1, 2022 ($10 million pretax as reported in this line item, $9 million after-tax)..
E Costs incurred for fair value adjustments to inventory and deferred revenue related to the acquisition of Cytiva in the six-month period ended July 2, 2021 ($46
million pretax as reported in this line item, $36 million after-tax).
F Gain on disposition of certain product lines in the six-month period ended July 2, 2021 ($13 million pretax as reported in this line item, $10 million after-tax).
G This line item reflects the aggregate tax effect of all nontax adjustments reflected in the preceding line items of the table. In addition, the footnotes above
indicate the after-tax amount of each individual adjustment item. Danaher estimates the tax effect of each adjustment item by applying Danaher’s overall
estimated effective tax rate to the pretax amount, unless the nature of the item and/or the tax jurisdiction in which the item has been recorded requires application
of a specific tax rate or tax treatment, in which case the tax effect of such item is estimated by applying such specific tax rate or tax treatment. The MCPS
dividends are not tax deductible and therefore the tax effect of the adjustments does not include any tax impact of the MCPS dividends.
H Discrete tax adjustments and other tax-related adjustments for the three-month period ended July 1, 2022, include the impact of net discrete tax benefits of $8
million related primarily to changes in estimates associated with prior period uncertain tax positions and excess tax benefits from stock-based compensation.
Discrete tax adjustments and other tax-related adjustments for the six-month period ended July 1, 2022, include the impact of net discrete tax benefits of $49
million related primarily to excess tax benefits from stock-based compensation and changes in estimates associated with prior period uncertain tax positions.
Discrete tax adjustments and other tax-related adjustments for the three-month period ended July 2, 2021, include the impact of net discrete tax benefits of $76
million related primarily to the release of reserves for uncertain tax positions due to the expiration of the statutes of limitation, audit settlements and excess tax
benefits from stock-based compensation, net of changes in estimates associated with prior period uncertain tax positions. Discrete tax adjustments and other tax-
related adjustments for the six-month period ended July 2, 2021, include the impact of net discrete tax benefits of $120 million related primarily to the release of
reserves for uncertain tax positions due to the expiration of statutes of limitation, audit settlements and excess tax benefits from stock-based compensation, net of
changes in estimates associated with prior period uncertain tax positions.
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
12

-- 14 of 22 --

I In March 2019, the Company issued $1.65 billion in aggregate liquidation preference of 4.75% MCPS Series A. In May 2020, the Company issued $1.72 billion
in aggregate liquidation preference of 5.0% MCPS Series B. Dividends on the MCPS Series A were, and on the Series B are, payable on a cumulative basis at an
annual rate of 4.75% and 5.0%, respectively, on the liquidation preference of $1,000 per share. Each share of MCPS Series A converted on April 15, 2022 into
6.6632 shares of Danaher’s common stock. Unless earlier converted, each share of MCPS Series B will automatically convert on April 15, 2023 into between
5.0130 and 6.1409 shares of Danaher’s common stock, subject to further anti-dilution adjustments. The number of shares of Danaher’s common stock issuable
on conversion of the MCPS is determined based on the volume weighted average price (“VWAP”) per share of the Company's common stock over the 20
consecutive trading day period beginning on, and including, the 21st scheduled trading day immediately April 15, 2023 for the Series B. For the calculation of
net earnings per common share from continuing operations, the impact of the dilutive MCPS is calculated under the if-converted method and the related MCPS
dividends are excluded. For the purposes of calculating adjusted earnings per common share from continuing operations, the Company has excluded the paid and
anticipated MCPS cash dividends and assumed the “if-converted” method of share dilution (the incremental shares of common stock deemed outstanding
applying the “if-converted” method of calculating share dilution only with respect to any MCPS the conversion of which would be dilutive in the particular
period are referred to as the “Converted Shares”) for any MCPS that were anti-dilutive for the given period. For additional information about the impact of the
MCPS on the calculation of diluted EPS, see note 6 in the Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding table below.
J Net earnings from continuing operations for calculation of diluted earnings per common share is summarized as follows ($ in millions):
Three-Month Period Ended Six-Month Period Ended
July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021
Net earnings from continuing operations $ 1,680 $ 1,699 $ 3,405 $ 3,401
MCPS dividends (22) (41) (63) (82)
Net earnings from continuing operations attributable to common stockholders for Basic EPS 1,658 1,658 3,342 3,319
Adjustment for MCPS dividends for dilutive MCPS — 20 20 40
Net earnings from continuing operations attributable to common stockholders after assumed
conversions for Diluted EPS $ 1,658 $ 1,678 $ 3,362 $ 3,359
DANAHER CORPORATION
Other Non-GAAP Adjusted P&L Measures
($ in millions, except per share data)
13

-- 15 of 22 --

Forecasted
Three-Month Period Ended Six-Month Period Ended Three-Month
Period Ending Year Ending
July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021 September 30,
2022 December 31,
2022
Average common stock and common equivalent shares
outstanding - diluted (GAAP) 6 736.0 736.0 736.8 735.6 736.3 737.1
Converted shares 7 8.6 8.6 8.6 8.6 8.6 8.6
Adjusted average common stock and common equivalent shares
outstanding - diluted (non-GAAP) 744.6 744.6 745.4 744.2 744.9 745.7
6 The impact of the MCPS Series A calculated under the if-converted method was dilutive for both the three and six-month periods ended July 1, 2022 and July 2, 2021, and as such
1.1 million and 6.0 million shares for the three and six-month periods ended July 1, 2022, respectively, and 11.0 million shares, for both the three and six-month periods ended July 2,
2021, underlying the MCPS Series A were included in the calculation of diluted EPS. The related MCPS Series A dividends of $20 million for the six-month period ended July 1, 2022
and $20 million and $40 million for the three and six-month periods ended July 2, 2021, respectively, were excluded from the calculation of net earnings for diluted EPS. On April 15,
2022, all outstanding shares of the MCPS Series A converted into 11.0 million shares of the Company’s common stock. There were no MCPS Series A dividends declared in the second
quarter of 2022 prior to their conversion and the MCPS Series A were dilutive for all periods prior to the conversion.
Additionally, for the year ending December 31, 2022, the impact of the MCPS Series A calculated under the if-converted method is forecasted to be dilutive and as such, approximately 3.0
million shares for the period underlying the MCPS Series A are included in the calculation of diluted EPS.
The impact of the MCPS Series B calculated under the if-converted method was anti-dilutive for both the three and six-month periods ended July 1, 2022 and July 2, 2021, and as such 8.6
million shares, for both the three and six-month periods underlying the MCPS Series B were excluded from the calculation of diluted EPS and the related MCPS Series B dividends of $22
million and $21 million for the three-month periods, respectively, and $43 million and $42 million for the six-month periods, respectively, were included in the calculation of net earnings
for diluted EPS.
Additionally, for the three-month period ending September 30, 2022 and the year ending December 31, 2022, the impact of the MCPS Series B calculated under the if-converted method is
forecasted to be anti-dilutive and as such, approximately 8.6 million shares for both periods underlying the MCPS Series B are excluded from the calculation of diluted EPS.
7 The number of converted shares assumes the conversion of all MCPS and issuance of the underlying shares applying the “if-converted” method of accounting and using an average 20
trading-day trailing VWAP of $250.49 and $258.03 as of July 1, 2022 and July 2, 2021, respectively.
DANAHER CORPORATION
Adjusted Average Common Stock and Common Equivalent Diluted Shares Outstanding
(shares in millions)
14

-- 16 of 22 --

Segments
Total Company Life Sciences Diagnostics
Environmental
& Applied
Solutions
Three-Month Period Ended July 2, 2021 Operating Profit Margins from Continuing
Operations (GAAP) 27.80 % 30.60 % 27.80 % 24.40 %
Second quarter 2022 impact from operating profit margins of businesses that have been owned
for less than one year or were disposed of during such period and did not qualify as discontinued
operations (0.30) (1.00) 0.45 0.10
Second quarter 2022 impairment charge related to technology and customer relationships in the
Environmental & Applied Solutions segment (0.10) — — (0.70)
Year-over-year core operating profit margin changes for the second quarter 2022 (defined as
all year-over-year operating profit margin changes other than the changes identified in the line
items above) (non-GAAP) 1.00 — 2.95 1.30
Three-Month Period Ended July 1, 2022 Operating Profit Margins from Continuing Operations
(GAAP) 28.40 % 29.60 % 31.20 % 25.10 %
Segments
Total Company Life Sciences Diagnostics
Environmental
& Applied
Solutions
Six-Month Period Ended July 2, 2021 Operating Profit Margins from Continuing Operations
(GAAP) 28.40 % 31.50 % 28.20 % 24.80 %
First half of 2022 impact from operating profit margins of businesses that have been owned for
less than one year or were disposed of during such period and did not qualify as discontinued
operations (0.35) (1.25) 0.45 0.30
Second quarter 2022 impairment charge related to technology and customer relationships in the
Environmental & Applied Solutions segment, net of first quarter 2021 impairment charge related
to a trade name in the Diagnostics segment — — 0.25 (0.35)
First half of 2022 impairments of accounts receivable and inventory as well as accruals for
contractual obligations in Russia (0.25) (0.50) (0.05) (0.05)
First half of 2021 acquisition-related fair value adjustments to inventory and deferred revenue
related to the acquisition of Cytiva 0.35 0.65 — —
Year-over-year core operating profit margin changes for first half of 2022 (defined as all year-
over-year operating profit margin changes other than the changes identified in the line items
above) (non-GAAP) 0.25 (1.20) 3.55 (1.90)
Six-Month Period Ended July 1, 2022 Operating Profit Margins from Continuing Operations
(GAAP) 28.40 % 29.20 % 32.40 % 22.80 %
Note: The Company deems acquisition-related transaction costs incurred in a given period to be significant (generally relating to the Company’s larger acquisitions) if it
determines that such costs exceed the range of acquisition-related transaction costs typical for Danaher in a given period.
DANAHER CORPORATION
Year-Over-Year Core Operating Margin Changes from Continuing Operations
15

-- 17 of 22 --

Three-Month Period Ended Year-over-Year
Change
Six-Month Period Ended Year-over-Year
Change	July 1, 2022 July 2, 2021 July 1, 2022 July 2, 2021
Total Cash Flows from Continuing Operations:
Net cash provided by operating activities from continuing
operations (GAAP) $ 2,000 $ 2,120 $ 3,968 $ 3,991
Total cash used in investing activities from continuing operations
(GAAP) $ (400) $ (1,067) $ (903) $ (2,060)
Total cash used in financing activities from continuing operations
(GAAP) $ (1,160) $ (139) $ (1,434) $ (588)
Free Cash Flow from Continuing Operations:
Net cash provided by operating activities from continuing
operations (GAAP) $ 2,000 $ 2,120 ~ (5.5) % $ 3,968 $ 3,991 ~ (0.5) %
Less: payments for additions to property, plant & equipment
(capital expenditures) from continuing operations (GAAP) (296) (305) (546) (556)
Plus: proceeds from sales of property, plant & equipment (capital
disposals) from continuing operations (GAAP) 7 1 9 13
Free cash flow from continuing operations (non-GAAP) $ 1,711 $ 1,816 ~ (6.0) % $ 3,431 $ 3,448 ~ (0.5) %
Free Cash Flow from Continuing Operations to Net Earnings
from Continuing Operations Conversion Ratio:
Free cash flow from continuing operations from above (non-
GAAP) $ 1,711 $ 1,816 $ 3,431 $ 3,448
Net earnings from continuing operations (GAAP) 1,680 1,699 3,405 3,401
Free cash flow from continuing operations to net earnings from
continuing operations conversion ratio (non-GAAP) 1.02 1.07 1.01 1.01
We define free cash flow from continuing operations as operating cash flows from continuing operations, less payments for additions to property, plant and equipment from continuing
operations (“capital expenditures”) plus the proceeds from sales of plant, property and equipment from continuing operations (“capital disposals”). All amounts presented above reflect only
continuing operations.
DANAHER CORPORATION
Free Cash Flow from Continuing Operations and Free Cash Flow from Continuing Operations to Net Earnings from Continuing Operations Conversion Ratio
($ in millions)
16

-- 18 of 22 --

Each of the non-GAAP measures set forth above should be considered in addition to, and not as a replacement for or superior to, the comparable GAAP measure, and may
not be comparable to similarly titled measures reported by other companies. Management believes that these measures provide useful information to investors by offering
additional ways of viewing Danaher Corporation’s (“Danaher” or the “Company”) results that, when reconciled to the corresponding GAAP measure, help our investors
to:
• with respect to the profitability-related non-GAAP measures, understand the long-term profitability trends of our business and compare our profitability to prior
and future periods and to our peers;
• with respect to core sales and related sales measures, identify underlying growth trends in our business and compare our sales performance with prior and future
periods and to our peers; and
• with respect to free cash flow from continuing operations and related cash flow measures (the “FCF Measure”), understand Danaher’s ability to generate cash
without external financings, strengthen its balance sheet, invest in its business and grow its business through acquisitions and other strategic opportunities
(although a limitation of free cash flow is that it does not take into account the Company’s debt service requirements and other non-discretionary expenditures,
and as a result the entire free cash flow amount is not necessarily available for discretionary expenditures).
While we expect overall demand for the Company’s COVID-19 related products to moderate as and to the extent the pandemic subsides, as the pandemic evolves toward
endemic status we believe a level of demand for the Company’s products that support COVID-19 related vaccines and therapeutics (including initiatives that seek to
prevent or mitigate similar, future pandemics) and COVID-19 testing will continue. However, on a relative basis, we expect the level of ongoing demand for products
supporting COVID-19 testing will be subject to more fluctuations in demand than the level of demand for products supporting COVID-19 related vaccines and
therapeutics. Therefore, beginning with the first quarter of 2022, in addition to disclosing core revenue growth, we disclose “base business core sales growth” on a basis
that excludes revenues related to COVID-19 testing and includes revenues from products that support COVID-19 related vaccines and therapeutics. We believe this
additional measure provides useful information to investors by facilitating period-to-period comparisons of our financial performance and identifying underlying growth
trends in the Company’s business that otherwise may be obscured by fluctuations in demand for COVID-19 testing as a result of the pandemic.
Management uses these non-GAAP measures to measure the Company’s operating and financial performance, and uses core sales and non-GAAP measures similar to
Adjusted Diluted Net Earnings Per Common Share from Continuing Operations and the FCF Measure in the Company’s executive compensation program.
• The items excluded from the non-GAAP measures set forth above have been excluded for the following reasons:
◦ Amortization of Intangible Assets. We exclude the amortization of acquisition-related intangible assets because the amount and timing of such charges
are significantly impacted by the timing, size, number and nature of the acquisitions we consummate. While we have a history of significant acquisition
activity we do not acquire businesses on a predictable cycle, and the amount of an acquisition’s purchase price allocated to intangible assets and related
amortization term are unique to each acquisition and can vary significantly from acquisition to acquisition. Exclusion of this amortization expense
facilitates more consistent comparisons of operating results over time between our newly acquired and long-held businesses, and with both acquisitive
and non-acquisitive peer companies. We believe however that it is important for investors to understand that such intangible assets contribute to sales
generation and that intangible asset amortization related to past acquisitions will recur in future periods until such intangible assets have been fully
amortized.
◦ Restructuring Charges. We exclude costs incurred pursuant to discrete restructuring plans that are fundamentally different (in terms of the size, strategic
nature and planning requirements, as well as the inconsistent frequency, of such plans) from the ongoing productivity improvements that result from
application of the Danaher Business System. Because these restructuring plans are incremental to the core activities that arise in the ordinary course of
our business and we believe are not indicative of Danaher’s ongoing operating costs in a given period, we exclude these costs to facilitate a more
consistent comparison of operating results over time.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
17

-- 19 of 22 --

◦ Other Adjustments. With respect to the other items excluded from Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we
exclude these items because they are of a nature and/or size that occur with inconsistent frequency, occur for reasons that may be unrelated to Danaher's
commercial performance during the period and/or we believe that such items may obscure underlying business trends and make comparisons of long-
term performance difficult. For example, we excluded the first quarter 2022 charge for asset impairments, accruals for contractual obligations and
similar items related to our Russia operations because, even though it is possible we could incur additional charges in the future, we do not believe these
charges are indicative of Danaher’s ongoing operating costs.
• With respect to adjusted average common stock and common equivalent shares outstanding, Danaher’s Mandatory Convertible Preferred Stock (“MCPS”) Series
A converted into Danaher common stock on April 15, 2022 and MCPS Series B will mandatorily convert into Danaher common stock on the mandatory
conversion date, which is expected to be April 15, 2023 (unless converted or redeemed earlier in accordance with the terms of the applicable certificate of
designations). With respect to the calculation of Adjusted Diluted Net Earnings Per Common Share from Continuing Operations, we apply the “if converted”
method of share dilution to the MCPS Series A and B in all applicable periods irrespective of whether such preferred shares would be dilutive or anti-dilutive in
the period. We believe this presentation provides useful information to investors by helping them understand what the net impact will be on Danaher’s earnings
per share-related measures once the MCPS convert into Danaher common stock.
• With respect to core operating profit margin changes, in addition to the explanation set forth in the bullets above relating to the “other adjustments”, we exclude
the impact of businesses owned for less than one year (or disposed of during such period and not treated as discontinued operations) because the timing, size,
number and nature of such transactions can vary significantly from period to period and may obscure underlying business trends and make comparisons of long-
term performance difficult.
• We calculate adjusted EBITDA by adding to operating profit amounts equal to depreciation and amortization and making the other adjustments reflected in the
applicable tables above, which allows us to calculate and disclose such measure by segment. Given Danaher’s diversification, we believe this helps our investors
compare the profitability of our individual segments to peer companies with like business lines.
• With respect to core sales related measures, (1) we exclude the impact of currency translation because it is not under management’s control, is subject to
volatility and can obscure underlying business trends, and (2) we exclude the effect of acquisitions and divested product lines because the timing, size, number
and nature of such transactions can vary significantly from period-to-period and between us and our peers, which we believe may obscure underlying business
trends and make comparisons of long-term performance difficult.
• With respect to the FCF Measure, we exclude payments for additions to property, plant and equipment (net of the proceeds from capital disposals) to demonstrate
the amount of operating cash flow for the period that remains after accounting for the Company’s capital expenditure requirements.
With respect to forecasted core sales related measures, we do not reconcile these measures to the comparable GAAP measure because of the inherent difficulty in
predicting and estimating the future impact and timing of currency translation, acquisitions and divested product lines, which would be reflected in any forecasted GAAP
revenue.
DANAHER CORPORATION
Statement Regarding Non-GAAP Measures
18

-- 20 of 22 --

Three-Month
Period Ending Year Ending
September 30, 2022 December 31, 2022
COVID-19 testing sales ~$325 ~$2,500
Impact of currency exchange rates on sales 8 ~(6.0)% ~(4.5)%
Operating profit fall-through 9 ~25.0%
Corporate expense 10 ~$(75) ~$(295)
Non-service components of periodic benefit costs (as included in Other income (expense), net in the Consolidated Condensed
Statements of Earnings) ~$10 - $15 ~$35 - $45
Interest expense, net 11 ~$(50) - $(55) ~$(200) - $(210)
Effective tax rate ~19.5% ~19.5%
8 This line item is not a forecast. The impact to the Company’s sales for the indicated periods is calculated using the assumption that the currency exchange rate for the euro is at par with
the U.S. dollar for the remainder of 2022 and that all other currency exchange rates in effect as of July 15, 2022 prevail throughout the remainder of 2022, and estimates the impact to the
Company’s sales for the indicated periods based on such assumptions. For the year ending December 31, 2022, this assumption reduces second half of 2022 sales by approximately $400
million versus the prevailing currency exchange rates as of April 20, 2022
9 Operating profit fall-through is defined as the percentage that results from dividing the assumed increase in operating profit (from incremental period-over-period sales) by the amount of
incremental period-over-period sales. This line item is not a forecast and the operating profit fall-through is calculated assuming the forecasted core sales growth and the currency
exchange rates described in note 8 above.
10 Corporate expense represents the operating profit (GAAP) for the Other segment, which consists of unallocated corporate costs and other costs not considered part of management’s
evaluation of reportable segment operating performance.
11 Interest expense, net is defined as interest expense net of interest income. This line item is an assumption rather than a forecast. The estimated interest expense, net is calculated assuming
the currency exchange rates in effect as of July 1, 2022 are to prevail throughout the remainder of the periods indicated and assuming interest rate increases in both periods indicated.
DANAHER CORPORATION
Supplemental Information
($ in millions)
19

-- 21 of 22 --

20

-- 22 of 22 --